New findings show that the stage of normal cell development at which B cells transform into leukemic cells impacts treatment ...

A new study shows that the stage of normal cell development at which B cells transform into leukemic cells impacts treatment ...

Scientists at St. Jude Children’s Research Hospital and University Health Network showed that the stage of B-cell development ...

New findings show that the stage of normal cell development at which B cells transform into leukemic cells impacts treatment ...

The server encountered an error and could not complete your request. If the problem persists, please contact us using the ...

It affects the B cell lymphocytes. Around 75 out of every 100 people with ALL (around 75%) are this type. B cell ALL can be further divided into subgroups, the most common subgroup is precursor B cell ...

Blinatumomab Plus Chemotherapy New Standard for Children With B-Cell ALL — 3-year disease-free survival rate was 96% with blinatumomab versus 87.9% with chemo alone.

In a clinical trial led by University of Toronto researchers, an allogeneic stem cell–derived islet therapy (zimislecel) ...

The FELIX study assessed efficacy of obe-cel among 127 adults (median age, 47 years; range, 20-81; 51.9% male) with relapsed or refractory B-cell ALL. Study participants had received a median two ...

Of the patients, 22.8% had extramedullary disease, and 28.3% had Philadelphia chromosome-positive B-cell ALL. Bridging therapy was administered to 92.9% of patients. Disclosures ...

Did non-relapse mortality rates vary by CAR T cell therapy product and how may this inform treatment choice? Yes. Among patients with large B cell lymphoma, we found a higher NRM rate of 7.4% in ...

Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical. ... Merck expects to record a pre-tax charge of approximately $750 million ...